MMulti-Immune HR
A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 2
- Enrollment
- 50 patients (estimated)
- Sponsors
- University of Arkansas for Medical Sciences (UAMS)
- Collaborators
- Johnson & Johnson
- Tags
- Bispecific Antibody, B-Cell Maturation Antigen (BCMA), GPRC5D, Minimal Residual Disease (MRD)
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 2134
- NCT Identifier
- NCT07029776
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.